NEW YORK Nov 12, 2012 -- Duchenne muscular dystrophy (DMD) patients treated with Sarepta Therapeutics' (SRPT) eteplirsen continue to do well on therapy, according to the company's chief medical officer speaking at the Action Duchenne meeting held this weekend in London.
JMP Securities analyst Liisa Bayko was in London attending the meeting, where Sarepta's chief medical officer Dr. Ed Kaye discussed results from the eteplirsen phase II study. In a note to clients this morning, Bayko writes:
The next catalyst for Sarepta will be 62-week , which we believe may be presented in January in San Francisco, and Dr. Kaye noted that the patients continue to do well on therapy with no decline in function nor missed infusions or discontinuations.
Bayko also learned that GlaxoSmithKline (GSK) andProsensa won't release results from controlled studies of their competing DMD drug drisapersen until the third quarter 2013. Again, Bayko:
GSK disclosed that it is committed to a full development program and will not release data from the Phase 2 placebo controlled study until 3Q13 at the earliest, and it is targeting 2014-15 for approval. In our view, this removes some risk from Sarepta -- in the event that it is enrolling a Phase 3 program in 2014, drisapersen will not yet be commercially available and competing for patients.
Glaxo and Prosensa's larger drisapersen phase III study is also ongoing with data not expected until the fourth quarter 2013, according to Bayko's account of Glaxo's presentation at the Action Duchenne meeting...